Skip to main content

Advertisement

SpringerLink
Log in

Phase I/II evaluation of Pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

The purpose of this study was to determine the efficacy and toxicity of pentostatin (2′-deoxycoformycin) administered in a five day schedule every 28 days to patients with B-cell chronic lymphocytic leukaemia (B-CLL) relapsed from or refractory to at least one line of prior chemotherapy. The initial dose level of 2 mg/m2/day was adjusted up or down by 0.5 mg/m2 in subsequent cycles on the basis of haematological and non-haematological toxicities. The five day schedule was selected because published pharmacokinetic studies had indicated that although pentostatin had an elimination half-life of approximately six hours and could inhibit plasma adenosine deaminase activity for 24 hours, recovery of enzyme activity rapidly took place and accumulation of dATP which has a toxic effect on non-replicating lymphoid cells could be increased by repeated dosing. Twenty-nine patients were entered into the study and dose-escalation was possible in nine, while dose reductions were required for five patients. Of the 24 patients evaluable for response, complete responses were achieved in two and partial responses in five for an overall response rate of 29.2%. Toxicity consisted of myelosuppression, infection, nausea and vomiting and hepatotoxicity but was experienced at acceptable levels considering the heavily pre-treated nature of the patient population. Pentostatin in this schedule has salvage activity in previously treated or resistant patients with B-CLL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Woo PWK, Dion HW, Lange SM, Dahl LF, Durham LJ: A novel adenosine and Ara-A deaminase inhibitor, (R)-3–(2–deoxy-beta-D-erythropentofuranosyl)-3,6,7,8 tetrahydroimidazo (4,5–d)(1,3)diazepin-8–ol. J Heterocycl Chem 11: 641– 643, 1974

    Google Scholar 

  2. Agarwal RP, Spector T, Parks RE Jr: Tight-binding inhibitors. IV. Inhibition of adenosine deaminases by various inhibitors. Biochem Pharmacol 26: 359–367, 1977

    Google Scholar 

  3. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ: Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2: 1067–1069, 1972

    Google Scholar 

  4. Cohen A, Hirschhorn R, Horowitz SD, Rubinstein A, Polmar SH, Hong R, Martin DW Jr: Deoxyadenosine triphosphates as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci USA 75: 472–476, 1978

    Google Scholar 

  5. Paine RA, Smyth JF, Harrap KR: Biochemical consequences of treatment with adenosine deaminase inhibitor 2′-deoxycoformycin. In: Rapado A, Watts R W E, De Bruyn C H HM (eds) Proceeding of the second half of the third international symposium on Purine Metabolism in man. Advances in Exp Med Biol vol 122b. Plenum Press, New York 1980, pp 365–371

    Google Scholar 

  6. Plunkett W, Benjamin RS, Keating MJ, Freireich EJ: Modulation of 9–ß-D-arabinofuranosyladenine 50–triphosphate and deoxyadenosine triphosphate in leukemic cells by 2′-deoxycoformycin during therapy with 9–ß-Darabinofuranosyladenine. Cancer Research 42: 2092–2096, 1982

    Google Scholar 

  7. Smyth JF, Paine RM, Jackman AL, Harrap KR, Chassin MM, Adamson RH, Johns DG: The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin. Cancer Chemother Pharmacol 5: 93–101, 1980

    Google Scholar 

  8. Prentice HG, Smyth JF, Ganeshaguru K, Wonke B, Bradstock KF, Janossy G, Goldstone AH, Hoffbrand AV: Remission induction with adenosine deaminase inhibitor 2′-deoxycoformycin in thy-lymphoblastic leukaemia. Lancet 1: 170–172, 1980

    Google Scholar 

  9. Grever MR, Siaw MFE, Jacob WF, Neidhart JA, Miser JS, Coleman MS, Hutton JJ, Balcerzak SP: The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 57: 406–417, 1981

    Google Scholar 

  10. Grever MR, Coleman MS, Gray DP, Malspeis L, Balcerzak SP, Neidhart JA: Definition of safe, effective dosing regimen of 2′-deoxycoformycin with biochemical investigation. Cancer Treatment Symposia 2: 43–49, 1984

    Google Scholar 

  11. Spiers ASD, Parekh SJ, Bishop MB: Hairy-Cell Leukaemia: Induction of complete remission with pentostatin (2′-deoxycoformycin). J Clin Oncol 2: 1336–1342, 1984

    Google Scholar 

  12. Spiers ASD, Ruckdeschel JC, Horton J: Effectiveness of pentostatin (2′-deoxycoformycin) in refractory lymphoid neoplasms. Scand J Hematol 32: 130–134, 1984

    Google Scholar 

  13. Begleiter A, Glazer RI, Israels LG, Pugh L, Johnston JB: Induction of DNA strand breaks in chronic lymphocytic leukaemia following treatment with 2–deoxycoformycin in vivo and in vitro. Cancer Res 47: 2498–2503, 1987

    Google Scholar 

  14. Grever MR, Leiby JM, Kraut EH, Wilson HE, Neidhart JA, Wall RL, Balcerzak SP: Low-dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 3: 1196–1201, 1985

    Google Scholar 

  15. Dillman RO, Mick R, McIntyre OR: Pentostatin in chronic lymphocytic leukaemia: A phase II trial of Cancer and Leukemia Group B. J Clin Oncol 7: 433–438, 1989

    Google Scholar 

  16. Ho AD, Thaler J, Stryckmans P, Coiffier B, Luciani M, Sonneveld P, Lechner K, Rodenuis S, Peetermans ME, de Cataldo F, de Witte T, Suciu S, Solbu G, Bödewadt-Radzun S, Hunstein W, Zittoun R: Pentostatin in refractory chronic lymphocytic leukaemia: a phase II trial of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst 82: 1416–1420, 1990

    Google Scholar 

  17. Dearden C, Catovsky D: Deoxycoformycin in the treatment of mature B-cell malignancies. Br J Cancer 62: 4–5, 1990

    Google Scholar 

  18. Major PP, Agarwal RP, Kufe DW: Clinical pharmacology of deoxycoformycin. Blood 58: 91–96,1981

    Google Scholar 

  19. Malspeis L, Weinrib B, Staubus AE, Grever MR, Balcerzak SP, Neidhart JA: Clinical pharmacokinetics of 2′-deoxycoformycin. Cancer Treat Symposia 2: 7–15, 1984

    Google Scholar 

  20. Johnston JB, Lee K, Verburg L, Blondal J, Mowat MRA, Israels LG, Begleiter A: Induction of apoptosis in CD4+ prolymphocytic leukaemia by deoxyadenosine and 2′-deoxycoformycin. Leuk Res 16: 781–788, 1992

    Google Scholar 

  21. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48: 198–206, 1981

    Google Scholar 

  22. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting the results of cancer treatment. Cancer 47: 207–214,1981

    Google Scholar 

  23. International Workshop on Chronic Lymphocytic Leukaemia: Chronic lymphocytic leukemia: recommendations for diagnosis, staging and response criteria. Am Inter Med 110: 236–238, 1989

    Google Scholar 

  24. Gehan EA: The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chron Dis 13: 346–353, 1961

    Google Scholar 

  25. Storer B: Design analysis of phase I clinical trials. Biometrics 45: 925–937, 1989

    Google Scholar 

  26. The French Cooperative Group on CLL, Johnson SA, Simon AG, Löttler H, Ösby E, Juliusson G, Emmerich B, Wyld PJ, Hiddemann W: Multicentre prospective randimised trial of floudarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 347: 1432–1438, 1997

    Google Scholar 

  27. Larson RA, Mick R, Spielberger RT, O'Brien SM, Ratain MJ: Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced haematological malignancies. J Clin Oncol 14: 188–195, 1997

    Google Scholar 

  28. Cheson BD, Vena DA Foss FM, Sorensen JM: Neurotoxicity of purine analogs: a review. J Clin Oncol 12: 2216–2228, 1994

    Google Scholar 

  29. Sven A, Carrera CJ, Carson DA, Beutler E, Piro LD: 2–chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukaemia. Leukemia and Lymphoma (Suppl): 133– 138, 1991

    Google Scholar 

  30. Juliusson G, Liliemark J: Long-term survival following cladribine (2–chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Am Oncol 7: 373–379, 1997

    Google Scholar 

  31. Cheson BD: Infections and immunosuppressive complication of purine analog therapy. J Clin Oncol 13: 2431–2448, 1995

    Google Scholar 

  32. Myint H, Copplestone JA, Orchard J, Craig V, Curtin D, Prentice AG, Hamon MD, Oscier DG, Hamblin TJ: Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Brit J Haematol 91: 341–344, 1995

    Google Scholar 

  33. Byrd JC, Hestler AA, Weiss RB, Freiman J, Kweder SL, Diehl LF: Fatal recurrence of autoimmine hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemotytic anemia. Am Oncol 6: 300– 301, 1995

    Google Scholar 

  34. Juliusson G, Elmhorn-Rosenborg A, Liliemark J: Response to 2–chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. New Engl J Med 327: 1056–1061, 1992

    Google Scholar 

  35. Delannoy A, Hanique, Ferrant A: 2–chloro-deoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. Neg Engl J Med 328: 812, 1993

    Google Scholar 

  36. Saven A, Lemon RH, Piro LD: 2–chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. New Eng J Med 328: 812–813, 1993

    Google Scholar 

  37. O'Brien S, Kantarjian H, Beran M, Freireich E, Kornblau S, Coller C, Lerner S, Gilbreath J, Keating M: Fludarabine and cyclophosphamide therapy in chronic lymphocytic leukemia. Blood 88 (Suppl): 480a, 1996

    Google Scholar 

  38. Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJS, Catovsky D: Subcutaneous CAMPATH-1H in fludarabine-resistant/ relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Brit J Haematol 96: 617–619, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Taunton & Somerset Hospital, Taunton

    S.A. Johnson

  2. Royal Marsden Hospital, London

    D. Catovsky

  3. Leeds General Infirmary, Leeds

    J.A. Child

  4. Royal London Hospital, London

    A.C. Newland

  5. Birmingham Heartlands Hospital, Birmingham

    D.W. Milligan

  6. Hillingdon Hospital, Hillingdon, United Kingdom

    R. Janmohamed

Authors
  1. S.A. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Catovsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J.A. Child
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A.C. Newland
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D.W. Milligan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Janmohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johnson, S., Catovsky, D., Child, J. et al. Phase I/II evaluation of Pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. Invest New Drugs 16, 155–160 (1998). https://doi.org/10.1023/A:1006100900082

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006100900082

Search

Navigation